Mark Blumenkranz is Kedalion’s Executive Chairman and Co-founder, a noted serial entrepreneur and the Managing Director of Lagunita Biosciences. Dr Blumenkranz is also the HJ Smead Professor Emeritus of Ophthalmology at Stanford University and was departmental Chairman from 1997 to 2015 and the founding director of the Byers Eye Institute. He was a Founder and Director of Macusight, Peak Surgical, Optimedica Corporation, Adverum Biotechnologies, Oculeve and Digisight Corporation (now Verana Heath). He has also served on the Boards of Directors of a number of other private and publicly traded ophthalmic drug and medical device companies including Oculex Pharmaceuticals, OIS, Midlabs, Presbia, and Beaver-Visitec (BVI Inc). He completed the Stanford Executive Program in the Graduate School of Business in 2004 and received his undergraduate, Masters in Biochemical Pharmacology, and MD from Brown University (AOA), where he is a Fellow of the Corporation and Immediate Past Chair of the Medical School Committee.